

FREEDOM OF INFORMATION ACT 2000**ROYAL CORNWALL HOSPITALS NHS TRUST****RESEARCH AND DEVELOPMENT**

Date request received	16/07/2025	FOI Ref	29562
------------------------------	------------	----------------	-------

Details of FOI Request

Q3.	Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?
-----	---

RESPONSE

Study Short Title	Study Full Title	Active Participants
KEYNOTE-866	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-Eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-866)	1 in follow-up
Phase II Trial of Trimodality Therapy +/- Durvalumab in Bladder Cancer BL13	A randomized phase II trial assessing trimodality therapy with or without adjuvant durvalumab (MEDI4736) to treat patients with muscle-invasive bladder cancer	2 in follow-up
SUNRISE 3	A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants with BCG Naïve High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)	1 in follow-up

Additional Commentary

Request received by R&D 16/07/2025.

With reference to the clinical trial question (Q3), the data included relates to any clinical trials for the treatment of urothelial cancer which are currently recruiting participants or have participants under treatment or in follow-up.

The number of active participants relates to those participants currently undergoing treatment or in follow-up.

Thank you.